Cogent Biosciences Inc (COGT)

Cogent Biosciences, Inc. is a clinical-stage biotechnology company focused on precision therapies for genetically defined diseases. Its development pipeline centers on bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 testing that is designed to address KIT receptor mutations, including KIT D816V associated with systemic mastocytosis, as well as KIT exon 17 mutations seen in advanced gastrointestinal stromal tumors. The company is also advancing CGT4859, a Phase 1 FGFR2 inhibitor for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, an ErbB2 mutant program aimed at actionable mutations in solid tumors and CNS-involved indications; and CGT6297, a PI3Ka mutant-selective inhibitor. Cogent has a licensing agreement with Plexxikon Inc. covering the research, development, and commercialization of bezuclastinib. The company is headquartered in Waltham, Massachusetts.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.